breast cancer group names

Release time ：Dec-25,2024

Breast cancer is among the most prevalent malignancies in women, classified into various subtypes based on distinct pathological features and molecular biomarkers. These subtypes encompass, but are not limited to, hormone receptor-positive breast cancer, HER2-positive breast cancer, and triple-negative breast cancer. Each subtype has unique treatment approaches and prognostic implications.

Hormone receptor-positive breast cancer is the most prevalent, affecting approximately 70% of patients with breast cancer. This subtype is characterized by the expression of estrogen receptors (ER) and/or progesterone receptors (PR) on cancer cell surfaces, making it more responsive to hormonal therapies. HER2-positive breast cancer constitutes about 20%-25% of breast cancer cases, with an overexpression of the HER2 protein that accelerates cellular proliferation. Triple-negative breast cancer, defined by the absence of ER, PR, and HER2, presents a more challenging treatment scenario and is associated with a less favorable prognosis.

Timely medical consultation and adherence to standardized treatment protocols are imperative for breast cancer patients. Additionally, maintaining healthy lifestyle practices, such as abstaining from smoking, moderating alcohol intake, consuming a balanced diet, and engaging in regular physical activity, can significantly enhance therapeutic outcomes and overall quality of life. Throughout treatment, it is essential for patients to use medications responsibly under a physician's supervision, avoiding self-medication without proper guidance.